Der Nervenarzt

, Volume 77, Issue 12, pp 1439–1443

Diagnostik und Therapie von Parkinson-Demenz in der klinischen Praxis

Übersicht

Zusammenfassung

In den letzten Jahrzehnten erhielten bei der Parkinson-Erkrankung vornehmlich die motorischen Symptome und deren Therapie medizinische Beachtung. Jedoch rücken zunehmend auch nichtmotorische Symptome ins Bewusstsein; dazu gehören unter anderem kognitive Defizite. Eine Demenz im Rahmen einer Parkinson-Erkrankung ist häufiger als bislang angenommen. Nach durchschnittlich 8 Jahren werden bei ca. 40% der Parkinson-Patienten kognitive Defizite festgestellt. Die Demenz und die damit verbundenen Probleme bestimmen meist eher die Prognose der Parkinson-Erkrankung als die motorischen Symptome. Der Notwendigkeit einer standardisierten Diagnostik und adäquaten Therapie steht eine bislang geringe Studienlage gegenüber.

Schlüsselwörter

M. Parkinson Demenz Liquor cerebrospinalis Diagnostische Möglichkeiten Cholinesterasehemmer 

Diagnosis and clinical therapy for Parkinson’s disease

Summary

For decades, awareness of Parkinson’s disease mainly focused on the presence and treatment of motor symptoms. More and more other symptoms of this disease not related to the motor system now receive increased attention, including cognitive decline. Dementia in Parkinson’s disease occurs more often than initially was thought. After an average of 8 years, about 40% of these patients suffer from cognitive decline. The difficulties and related problems affect prognosis more than do the motor symptoms. There is a need for standardized diagnostic and specific therapeutic intervention, but appropriate studies are still lacking.

Keywords

Parkinson’s disease Dementia Cerebrospinal fluid Diagnostic options Cholinesterase inhibitors 

Literatur

  1. 1.
    Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18:937–941CrossRefPubMedGoogle Scholar
  2. 2.
    Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 10:1255–1263CrossRefGoogle Scholar
  3. 3.
    Andreasen N, Sjogren M, Blennow K (2003) CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 4:147–155CrossRefPubMedGoogle Scholar
  4. 4.
    Athey RJ, Porter RW, Walker RW (2005) Cognitive assessment of a representative community population with Parkinson’s disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing 34:268–273CrossRefPubMedGoogle Scholar
  5. 5.
    Bibl M, Mollenhauer B, Esselmann H et al. (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187CrossRefPubMedGoogle Scholar
  6. 6.
    Braak H, Rub U, Jansen Steur EN et al. (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410PubMedGoogle Scholar
  7. 7.
    Calabrese P, Kessler J (2000) DEMTECT. EISAI/Pfizer-Verlag, KarlsruheGoogle Scholar
  8. 8.
    Cummings JL (1988) Intellectual impairment in Parkinson’s disease: clinical, pathologic and biochemical correlates. J Geriatr Psychiatry Neurol 1:24–36PubMedGoogle Scholar
  9. 9.
    El-Agnaf OM, Salem SA, Paleologou KE et al. (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 17:1945–1947PubMedGoogle Scholar
  10. 10.
    Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2:229–237CrossRefPubMedGoogle Scholar
  11. 11.
    Emre M, Aarsland D, Albanese A et al. (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 24:2509–2518CrossRefGoogle Scholar
  12. 12.
    Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental-State. A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  13. 13.
    Gomez-Tortosa E, Gonzalo I, Fanjul S et al. (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60:1218–1222CrossRefPubMedGoogle Scholar
  14. 14.
    Hughes TA, Ross HF, Mindham RH et al. (2004) Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 110:118–123CrossRefPubMedGoogle Scholar
  15. 15.
    Jellinger KA, Seppi K, Wenning GK et al. (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339CrossRefPubMedGoogle Scholar
  16. 16.
    Kalbe E, Kessler J, Emmens D et al. (2005) PANDA. Ökonomische Erfassung kognitiver und affektiver Beeinträchtigungen bei der Parkinson Demenz. Akt Neurol 32(Suppl 4):223Google Scholar
  17. 17.
    Klein C (2006) Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 63:328–334CrossRefPubMedGoogle Scholar
  18. 18.
    Langston JW (2006) The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59:591–596CrossRefPubMedGoogle Scholar
  19. 19.
    McKeith IG, Del Ser T, Spano P et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet 356:2031–2036CrossRefPubMedGoogle Scholar
  20. 20.
    McKeith IG, Dickson DW, Lowe J et al. (2005) Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 65:1863–1872CrossRefPubMedGoogle Scholar
  21. 21.
    Mollenhauer B, Cepek L, Bibl M et al. (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19:164–170CrossRefPubMedGoogle Scholar
  22. 22.
    Parkinson J (1817) An essay on the shaking palsy. Neely & Jones, LondonGoogle Scholar
  23. 23.
    Parkkinen L, Kauppinen T, Pirttila T et al. (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91CrossRefPubMedGoogle Scholar
  24. 24.
    Press DZ (2004) Parkinson’s Disease dementia – A First step. N Engl J Med 24:2547CrossRefGoogle Scholar
  25. 25.
    Ravina B, Siderowf A, Farrar JT et al. (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crosssover study. J Neurol Neurosurg Psychiatry 76:934–939CrossRefPubMedGoogle Scholar
  26. 26.
    Riedel O, Dodel R, Spottke A et al. (2006) Wie beurteilen Ärzte die Häufigkeit demenzieller, depressiver und psychotischer Syndrome bei Patienten mit der Parkinson-Krankheit?—Eine Befragung von 500 Fachärzten im ambulanten Versorgungssektor Deutschlands. Akt Neurol 33: 374–380CrossRefGoogle Scholar
  27. 27.
    Rosenstein LD (1998) Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev 8:109–167CrossRefPubMedGoogle Scholar
  28. 28.
    Roth M, Huppert FA, Mountjoy CQ et al. (1999) CAMDEX—Revised. Cambridge University Press, CambridgeGoogle Scholar
  29. 29.
    Shulman KI, Shedletsky R, Silver IL (1986) The challenge of time: clockdrawing and cognitive function in the elderly. Int J Geriatr Psychiatry 1:135–140CrossRefGoogle Scholar
  30. 30.
    Sinanovic O, Kapidzic A, Kovacevic L et al. (2005) EEG frequency and cognitive dysfunction in patients with Parkinson’s disease. Med Arh 59:286–287PubMedGoogle Scholar
  31. 31.
    Spillantini MG, Schmidt ML, Lee VM et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840CrossRefPubMedGoogle Scholar
  32. 32.
    WHO (2005) Weltgesundheitsorganisation: Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F), 5. durchgesehene und ergänzte Auflage. Huber, BernGoogle Scholar
  33. 33.
    Wiltfang J, Lewczuk P, Riederer P et al. (2005) Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 6:69–84PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Center for Neurologic DiseasesBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Paracelsus-Elena-KlinikKasselDeutschland

Personalised recommendations